NCT07823075Not yet recruiting
Efficacy and Safety of Intrapleural Fibrinolytic Therapy in Tuberculous Pleural Effusion Versus Non-Tuberculous Pleural Infection
Efficacy and Safety of Intrapleural Fibrinolytic Therapy in Tuberculous Pleural Effusion Versus Non-Tuberculous Pleural Infection: A Ten-Year Retrospective Study at Hospital Canselor Tuanku Muhriz (FIB-TB Study)
Source: ClinicalTrials.gov · Last updated 16 Sept 2026
Brief summary (registry, in English)
This retrospective cohort study evaluates the efficacy and safety of intrapleural fibrinolytic therapy (tPA/DNase) in patients with tuberculous pleural effusion compared with non-tuberculous pleural infection at Hospital Canselor Tuanku Muhriz (HCTM), Malaysia. The study aims to compare radiological improvement, clinical outcomes, and treatment-related adverse events to provide evidence supporting the use of IPFT in tuberculous pleural effusion.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 160 (estimated)
- First submitted
- 2 Aug 2026
- Start date
- 20 Sept 2026
- Primary completion date
- 1 May 2027
- Lead sponsor
- National University of Malaysia
- NCT number
- NCT07823075
What you commit to
- Study type: Observational
- Planned participants: 160
- From 20 Sept 2026 to the primary completion date, 1 May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who received intrapleural fibrinolytic therapy as monotherapy with either tissue plasminogen activator or deoxyribonuclease alone.
Other illness
- Malignant and transudative pleural effusion
Other
- Incomplete medical records
Who the study is looking for
- Adults aged ≥18 years.
- Patients with tuberculous pleural effusion or non-tuberculous pleural effusion diagnosed based on clinical, radiological, laboratory, microbiological, histopathological, and/or pleuroscopic findings.
- Patients who received intrapleural fibrinolytic therapy with tissue plasminogen activator and deoxyribonuclease during the study period.
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National University of Malaysia Coordinator of this site? Confirm its status | Kuala Lumpur | Malaysia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.